ADVERTISEMENT

Afinitor Boosts Effectiveness of Hormonal Therapy

Adding Afinitor, an mTOR inhibitor, to tamoxifen helped women with metastatic breast cancer live about four months longer without their disease getting worse, according to a study presented Thursday at SABCS.

BY MELISSA WEBER
PUBLISHED THURSDAY, DECEMBER 9, 2010
Talk about this article with other patients, caregivers, and advocates in the Breast CURE discussion group.
Adding Afinitor (everolimus) to tamoxifen helped women with metastatic breast cancer live four months longer without their disease getting worse, according to a study presented Thursday at the San Antonio Breast Cancer Symposium.

Researchers randomly assigned 111 women to receive tamoxifen alone or tamoxifen plus Afinitor. Patients getting the combination lived a median of 8.6 months without disease progression, compared with 4.5 months for the tamoxifen-only group. After a median follow-up of around 22 months, nine patients in the combination arm had died compared with 25 deaths in the tamoxifen arm. All patients in this phase 2 trial had estrogen receptor–positive breast cancer that had previously been treated with an aromatase inhibitor, like Femara (letrozole) or Arimidex (anastrozole).

Afinitor—already approved for advanced kidney cancer—works by targeting mTOR, a protein that helps regulate the growth of cancer cells and blood vessels. Side effects associated with Afinitor include mouth ulcers, infections, cough and fatigue.

Three phase 3 studies, nicknamed BOLERO—short for Breast cancer trials of OraL EveROlimus— are now under way testing Afinitor in patients with locally advanced or metastatic breast cancer. one study will look at Afinitor in combination with the HER2-targeted drug Herceptin (trastuzumab) and the chemotherapy drug Taxol (paclitaxel). A second study will test the mTOR inhibitor in combination with Aromasin (exemestane), an aromatase inhibitor used to treat postmenopausal women with estrogen receptor–positive breast cancer. The third study will combine Afinitor with Herceptin and vinorelbine, a chemotherapy agent.

Talk about this article with other patients, caregivers, and advocates in the Breast CURE discussion group.
ADVERTISEMENT
ShareYourStory
Related Articles
Pregnancy and a Breast Cancer Diagnosis
BY ELEANOR MILLER
Eleanor Miller, a nurse at the University of Pennsylvania, writes about considerations for a patient who is pregnant with a breast cancer diagnosis.
Understanding the Characteristics and Behavior of Breast Cancer
BY LAURA MARTIN
Advances in molecular profiling technologies have made it easier to understand the molecular characteristics and clinical behavior of breast cancer.
Fear Less
A cancer diagnosis brings with it a world of fears, but living with advanced/terminal cancer puts the other fears into perspective.
Long-Term Cancer Treatment — A Patient’s Perspective
BY AIMEE SHAW
Having been a 12-year cancer survivor, metastatic since 2006, I’ve gained a lot of experience with what long-term palliative care looks and feels like.
I'm Going to Live Until I Die
Don't go to the funeral until the day of the funeral.
Related Videos
Jennifer Klemp on Survivorship for Patients With Hereditary Breast Cancer
BY JENNIFER KLEMP, PHD, MPH
Jennifer Klemp, PhD, MPH, director, Breast Cancer Survivorship Center, The University of Kansas Cancer Center, discusses survivorship for patients with hereditary breast cancer.
Jennifer Klemp Discusses Breast Cancer Survivorship
BY JENNIFER KLEMP, PHD, MPH
Jennifer Klemp, PhD, MPH, director, Breast Cancer Survivorship Center, The University of Kansas Cancer Center, discusses breast cancer survivorship.
Debu Tripathy Discusses a Clinical Trial of Ibrance in Breast Cancer
BY DEBU TRIPATHY
Debu Tripathy, editor-in-chief of CURE and chair of the Department of Breast Medical Oncology at The University of Texas MD Anderson Cancer Center, discusses adding the targeted drug Ibrance to the hormonal drug Faslodex.
Health Advocate Amy Byer Shainman Discusses Risk Management of Hereditary Cancers
When it comes to managing your risk of cancer, especially when dealing with a familial cancer risk, "what is right for one person, may not be right for another," says Amy Byer Shainman.
Research Updates on HER2-Positive Breast Cancer from the 2015 Miami Breast Cancer Conference
Debu Tripathy, editor-in-chief of CURE magazine, discusses updates from the Miami Breast Cancer Conference, including the changing landscape of HER2-positive breast cancer.
$auto_registration$